SLC5A2 and heart failure: Whether the effect of SGLT2 inhibition on outcomes in non-diabetic heart failure patients is class effect or drug-specific effect remains unclear (Packer et al., 2017; Maack et al., 2018; Santos-Gallego et al., 2019; Yurista et al., 2019).